Notably, a single apheresis was sufficient to target an adequate number of CD34+ cells for ASCT in 35(89.7%) patients with r/r lymphoma, with 76.9%(30/39) predicted PM patients achieving optimal collection within two apheresis sessions. The gene discussed is CD34; the disease is lymphoma.